Biotechnology News and Research

RSS

First patient dosed with rFVIIIFc in A-LONG trial

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.

6 Dec 2010

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

6 Dec 2010

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Inc., a member of the Roche Group, and Biogen Idec announced today positive data from a Phase III study of Rituxan (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).

6 Dec 2010

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

BioCryst Pharmaceuticals, Inc. announced the presentation of new data that confirms forodesine's clinical activity in the treatment of chronic lymphocytic leukemia at the 52nd Annual American Society of Hematology Meeting & Exposition being held in Orlando, Florida.

6 Dec 2010

$Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010$

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.

6 Dec 2010

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.

6 Dec 2010

Shrink's MetalFluor technology on front cover of Applied Physics Letters

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that Shrink's MetalFluor™ technology was studied, reported on and made the front cover of the November issue of Applied Physics Letters.

4 Dec 2010

Merck plans to acquire SmartCells

Today pharmaceutical company, Merck & Co., Inc. announced it will acquire SmartCells, Inc., a private biotech developing a glucose-responsive insulin whose proof-of-concept preclinical trials were partially funded by the Juvenile Diabetes Research Foundation.

4 Dec 2010

Discovery Labs plans to file request for hearing over Nasdaq delisting notification

Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.

3 Dec 2010

Biomagnetics updates prototype bench top version of IOBS biosensor

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced that an updated prototype bench top version of the Integrated Optical Biosensor, originally developed at Los Alamos for research purposes, is now complete.

3 Dec 2010

AHA: Incidence of hospitalization for heart valve diseases rises in New York

The incidence of hospitalization and treatment for heart valve diseases in New York State has constantly and progressively risen since the early 1980s, according to research presented at the recent meeting of the American Heart Association (AHA) by SUNY Downstate Medical Center. The study results were published in a supplement to the AHA journal, Circulation.

3 Dec 2010

Teva comments on Lovenox’s patent infringement lawsuit

Teva Pharmaceutical Industries Ltd. commented today on the patent infringement lawsuit filed by Momenta Pharmaceuticals, Inc. and Sandoz Inc.

3 Dec 2010

Advanced Cell Technology eliminates $3 million in debt, strengthens balance sheet

Advanced Cell Technology, Inc. announced today that it has strengthened its balance sheet through the elimination of approximately $3 million in debt over the past several weeks. The conversion of senior and subordinated debentures to equity has reduced the Company's outstanding convertible debentures to approximately $890,000. Since September 2009, Advanced Cell has eliminated approximately $33 million in indebtedness.

3 Dec 2010

Arteriocyte launches Stem Cell Expansion System for research use

Arteriocyte, Inc., a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies announced today the launch of its first commercially available Stem Cell Expansion System for research use.

2 Dec 2010

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that preliminary results from its cancer stem cell program, targeting the CD47 protein, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida, December 4-7, 2010.

2 Dec 2010

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen today announced that it will present data from several key Nplate (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.

2 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

SAFC Hitech plans new production facility in Taiwan for LED and silicon semiconductor precursors

Following the March 2010 production expansion of trimethylgallium (TMG) at its Bromborough, UK manufacturing site, SAFC Hitech®, a member of the Sigma-Aldrich® Group, reinforced its commitment to the Asia-Pacific electronics markets by announcing plans to build a new, dedicated facility in Kaohsiung, Taiwan for transfilling, technical service and production of LED and silicon semiconductor precursors.

2 Dec 2010

PreCision Dermatology formed as a result of spin-out of Onset Therapeutics

PreCision Dermatology Inc., a company focused on developing, manufacturing, acquiring and marketing a broad portfolio of innovative dermatology products, today announced it was formed as the result of the spin-out of Onset Therapeutics, a wholly-owned subsidiary of Collegium Pharmaceutical, Inc. PreCision Dermatology also announced the close of a Series A financing led by life science private equity investor Essex Woodlands.

2 Dec 2010

New visualization tool to foster understanding of science dynamics

A new set of tools released today by Science-Metrix Inc. seeks to improve the way we talk about and understand science from the classroom to the boardroom.

2 Dec 2010